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Abstract 
Evolocumab has been shown to consistently reduce low-density lipoprotein cholesterol (LDL-C) across populations. 
The phase 3 studies included administration in the home-use and in-clinic settings but did not specifically evaluate 
the feasibility of home-use administration. Two clinical studies enrolled patients with hypercholesterolemia or mixed 
dyslipidemia on statin therapy and with/without ezetimibe received evolocumab in the home-use setting. Patients 
were randomized to self-administer evolocumab using one of two injection devices biweekly over 6 weeks (autoin-
jector or prefilled syringe; n = 149; ClinicalTrials.gov, NCT01849497) or monthly over 12 weeks (autoinjector or auto-
mated minidoser; n = 164; NCT01879319). The first self-administration occurred in the in-clinic setting, and two more 
were performed in the at-home setting. Patients were successful in self-administering evolocumab in the home-use 
setting in approximately 95 % of attempts and experienced LDL-C reductions from baseline to week 6 or the mean 
of weeks 10 and 12 of approximately 65 %. Rates of successful self-administration and LDL-C reduction were similar 
across dosing schedules and study devices. Adverse events were similar between randomized groups and generally 
mild in severity. In two clinical studies, therefore, patients were able to successfully self-administer evolocumab in 
both the in-clinic and at-home settings regardless of which dosing schedule or device they used.
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Background
Evolocumab (AMG 145; Repatha®, Amgen Inc, Thou-
sand Oaks, CA) is a monoclonal antibody administered 
via subcutaneous injection that inhibits proprotein con-
vertase subtilisin/kexin type 9 (PCSK9) and has been 
shown to decrease low-density lipoprotein cholesterol 
(LDL-C) levels significantly and consistently across mul-
tiple populations with hypercholesterolemia (Koren et al. 
2014; Raal et al. 2015; Robinson et al. 2014; Sabatine et al. 
2015; Stroes et al. 2014; Blom et al. 2014). Evolocumab is 
approved for at-home administration by patients or their 
caregivers either 140  mg biweekly (administered via a 
1 mL autoinjector) or 420 mg monthly (three 1 mL auto-
injectors or one 3.5  mL automated minidoser [AMD]) 
(Amgen Inc 2015c). These two different dosing regimens 
provide similar LDL-C reduction, are clinically equiva-
lent (Koren et  al. 2014; Raal et  al. 2015; Robinson et  al. 
2014; Sabatine et  al. 2015; Stroes et  al. 2014), and are 
offered to accommodate patient preference.
Monoclonal antibodies self-administered in the home-
use setting are relatively new for the treatment of hyper-
cholesterolemia (Rader and Kastelein 2014). The LDL-C 
reduction and safety profile observed with PCSK9 inhibi-
tion [55–75 % in the evolocumab clinical program (Koren 
et al. 2014; Raal et al. 2015; Robinson et al. 2014; Stroes 
et  al. 2014; Sabatine et  al. 2015; Blom et  al. 2014)] pre-
sents compelling reason for eligible patients to initiate 
home-use administration of an injectable medication. 
Moreover, subcutaneously-injected biologics are widely 
used by patients with diseases such as rheumatoid arthri-
tis, psoriasis, and osteoporosis in the home-use setting 
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(Foltz et al. 2013; Hanley et al. 2012; American Academy 
of Dermatology Work Group et al. 2011).
Amgen’s evolocumab phase 2 and 3 development pro-
gram, known as Program to Reduce LDL-C and car-
diovascular Outcomes Following Inhibition of PCSK9 In 
different pOpulations (PROFICIO), reflects LDL-C reduc-
tion via PCSK9 inhibition in both the clinic and at-home 
settings. This program is composed of several completed 
studies that demonstrated safety and efficacy in hyperlipi-
demia and mixed dyslipidemia patients, as well as several 
ongoing studies that are evaluating safety and efficacy in 
the setting of atherosclerosis and secondary prevention 
(ClinicalTrials.gov, NCT01764633, NCT01813422, and 
NCT01984424). In the PROFICIO phase 2 studies (Stein 
et al. 2014), evolocumab was administered in the clinic by 
the healthcare practitioner, while in the 12-week, phase 3 
studies (Koren et al. 2014; Raal et al. 2015; Robinson et al. 
2014; Stroes et al. 2014), the initial one or two doses and 
the last dose were administered in the clinic (either by site, 
patient, or caregiver) and all other injections were admin-
istered at home by the patient or caregiver. Study drug and 
device safety were assessed separately via reports of AEs 
and adverse device effects, respectively. Though the pro-
gram design included both healthcare professional–super-
vised administration and home-use administration, these 
studies did not specifically examine whether patients could 
successfully self-administer evolocumab in the home-use 
setting.
In addition to the aforementioned program-wide 
assessment of home vs in-clinic administration, we 
performed two randomized studies (THOMAS-1 and 
THOMAS-2) with similar designs that specifically eval-
uated injection success of evolocumab in the home-use 
setting with three different devices. In this article, we 
report the primary results of the THOMAS studies.
Methods
THOMAS-1 (NCT01849497) and THOMAS-2 
(NCT01879319) were multicenter, open label, paral-
lel-arm, randomized studies that enrolled patients at 
22 and 23 sites (respectively) in the United States and 
Canada from April to December 2013. Patients with 
hypercholesterolemia or mixed dyslipidemia on sta-
tin therapy with or without ezetimibe were eligible. 
Enrolled patients were randomized to receive evo-
locumab administered at home with the prefilled 
SureClick® autoinjector vs a prefilled syringe (PFS) 
(THOMAS-1) or the prefilled SureClick® autoinjector 
vs an AMD (THOMAS-2).
Ethics, consent, and permissions
Both studies required written informed consent, adher-
ence to Good Clinical Practices and local regulations, and 
approval of the protocol by institutional review boards/
ethics committees.
Patient enrollment and study procedures
Patients were eligible for enrollment in the THOMAS 
studies if they were 18–80  years of age, taking an 
approved statin (with or without ezetimibe) at a stable 
dose for at least 4  weeks before LDL-C screening, and 
had a fasting LDL-C  ≥85  mg/dL and fasting triglycer-
ides ≤400 mg/dL. Exclusion criteria included the follow-
ing conditions or procedures: family or personal history 
of hereditary muscular disorders, moderate to severe 
heart failure, moderate to severe renal dysfunction, 
recent cardiovascular event or deep vein thrombosis/pul-
monary embolism, recent or planned revascularization/
cardiac surgery, type 1 diabetes, uncontrolled or recently-
diagnosed type 2 diabetes, infection, recent malignancy, 
and major cardiac, endocrine, major hematologic, renal, 
metabolic, and gastrointestinal disorders. Patients were 
excluded for current or recent use of the following drugs: 
lipid-lowering drugs or supplements other than statins 
or ezetimibe, drugs or supplements that potentially alter 
lipid metabolism or inhibit cytochrome p450 family 3 
subfamily A (CYP3A), and evolocumab or other PCSK9 
inhibitor. Female patients were excluded if they were 
pregnant, breast-feeding, intended to become pregnant, 
or were of childbearing potential and not using effective 
birth control. Finally, patients were excluded if they were 
enrolled in another investigational device or drug study.
During screening prospective enrollees received 1 
(THOMAS-1) or 3 (THOMAS-2) 1  mL placebo injec-
tions delivered via the PFS (THOMAS-1) or autoinjec-
tor (THOMAS-2) to confirm tolerance of subcutaneous 
injection; this period also included laboratory testing 
to confirm study eligibility. Patients who tolerated the 
screening and met eligibility criteria were randomized. 
Enrolled patients were randomized 1:1 by interactive 
voice/web-based response system to the autoinjec-
tor or PFS in THOMAS-1 and autoinjector or AMD in 
THOMAS-2. Randomization was stratified by baseline 
LDL-C <130 mg/dL vs ≥130 mg/dL.
Three total doses were administered over 6  weeks 
in THOMAS-1 (140  mg biweekly) and 12  weeks in 
THOMAS-2 (420  mg monthly). At the time of the first 
dose of evolocumab, the clinic healthcare practitioner 
trained the patient on how to use the device to safely 
deliver a full dose and reviewed the device’s instructions 
for use (see Additional file  1: Appendix for full training 
checklist). If applicable, the patient’s designee or car-
egiver was trained by the clinic staff on how to admin-
ister evolocumab with the study device. AEs, including 
adverse device effects, and device complaints were col-
lected at all visits.
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The first evolocumab dose was administered in the 
clinic under supervision of the staff, and the remaining 
doses were self-administered at home with the home-
use device(s) the patient was randomized to. At the first 
visit (day 1) and during telephone contacts (weeks 2 and 
4 in THOMAS-1, 4 and 8 in THOMAS-2), clinic staff 
documented whether the patient was able to adminis-
ter a full dose of evolocumab. Patients returned to the 
site for LDL-C measurement at week 6 in THOMAS-1 
and weeks 10 and 12 in THOMAS-2. The end of study 
visit was a telephone contact at week 8 for documenting 
AEs in THOMAS-1 and an in-clinic visit at week 12 in 
THOMAS-2.
Study drugs and devices
Evolocumab is a sterile, preservative-free solution. Inves-
tigators could prescribe any concomitant medications or 
treatments except for prohibited drugs or supplements 
that potentially lower lipids, affect lipid metabolism, or 
inhibit CYP3A.
The autoinjector used in the phase 3 evolocumab 
studies contained 140  mg of evolocumab in 1  mL total 
solution. The PFS, similarly, contained 140  mg of evo-
locumab. Each autoinjector or PFS injection was admin-
istered in up to three anatomical locations: abdomen, 
thigh, or outer arm (arm injections required caregiver 
assistance).
The AMD is a single-use, disposable, on-body elec-
tromechanical injection device. It was packaged with 
a prefilled cartridge assembly containing 420  mg of 
evolocumab in a 3.5 mL solution. All AMD injections 
were administered to the patient’s abdomen, thigh, 
or outer arm with arm injections requiring caregiver 
assistance.
Diagrams of the devices are displayed in the Appendix 
of Additional file 1.
Assessments
Successful administration of a full evolocumab dose 
in the at-home setting was assessed in telephone con-
tacts at weeks 2 and 4 of THOMAS-1 and 4 and 8 of 
THOMAS-2.
Fasting lipid assessments were taken at screening and 
day 1 in both THOMAS studies, week 6 in THOMAS-1, 
and weeks 10 and week 12 in THOMAS-2. LDL-C was 
determined in a reflexive manner by using the Friedewald 
equation (Friedewald et  al. 1972) unless the calculated 
LDL-C was <40 mg/dL or triglycerides were >400 mg/dL, 
in which case ultracentrifugation was used.
Blood samples were collected at day 1 and week 6 in 
THOMAS-1 and weeks 10 and 12 in THOMAS-2 to 
evaluate evolocumab concentration levels (pharma-
cokinetics [PK]) and PCSK9 levels (pharmacodynamics 
[PD]), as well as anti-evolocumab antibodies. PK and PD 
analyses were conducted and presented descriptively by 
study device. If samples tested positive for binding anti-
evolocumab antibodies, they were also tested for neutral-
izing antibodies.
AEs and serious AEs were documented at all visits. 
Treatment-emergent AEs were defined as those occur-
ring with an onset after the first administration of study 
drug and before the end of study visit, and investigators 
were asked to assess whether there was a reasonable pos-
sibility that the events were related to evolocumab or 
device. Adverse device effects were treatment-emergent 
AEs that the investigator deemed possibly related to the 
device. Investigators were trained about intentional use 
before enrolling patients.
Deaths and cardiovascular events were adjudicated by 
an independent clinical endpoint committee (TIMI Study 
Group, Boston, MA) composed of independent members 
blinded to patient identity, treatment assignment, and 
LDL-C concentrations.
Endpoints
The primary endpoint of both THOMAS studies was 
the patient-reported successful outcome of attempted 
self-administered full-dose of evolocumab in the home-
use setting with the study device (autoinjector or PFS 
in THOMAS-1, autoinjector or AMD in THOMAS-2). 
The secondary endpoint was the mean change in LDL-C 
from baseline to 6 weeks in THOMAS-1 and the mean of 
weeks 10 and 12 in THOMAS-2.
Statistical analysis
The THOMAS studies did not test a formal hypoth-
esis. For the analysis of the primary endpoint in both 
studies, the proportion of patients who successfully 
self-administered a full dose of evolocumab at each of 
the two home visits was reported. The 95  % confidence 
intervals (CIs) for the proportions were calculated using 
the Wilson score interval. The secondary endpoint was 
estimated percent change from baseline in LDL-C to 
week 6 in THOMAS-1 and the mean of weeks 10 and 
12 in THOMAS-2. In THOMAS-1, this outcome was 
estimated using an analysis of covariance model that 
included study device and LDL-C stratum (i.e.,  <130   
mg/dL vs  ≥130  mg/dL). In THOMAS-2, the outcome 
was estimated using a repeated-measures mixed-effects 
model that included the screening LDL-C stratum, study 
device, visit, and study device by visit. Prespecified sub-
group analyses included age (<65  years and  ≥65  years) 
and sex. AEs, deaths, and adjudicated cardiovascular 
events were summarized and are presented descriptively. 
Analyses were conducted using SAS version 9.2 or later 
(SAS Institute, Cary, NC).
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Results
In the THOMAS-1 study, 271 patients were screened, 
149 were randomized (autoinjector: n = 74, PFS: n = 75), 
and 144 completed the study (97 %). In the THOMAS-2 
study, 243 patients were screened, 164 were randomized 
(autoinjector: n = 82, AMD: n = 82), and 157 completed 
the study (96  %). Patient disposition is displayed in the 
Appendix of Additional file 1.
The patient profiles of THOMAS-1 and THOMAS-2 
were similar and balanced between study device groups 
(Table  1): 45  % of patients from both studies were 
women, the mean age was 60  years, 19  % had coronary 
artery disease, 22  % had type 2 diabetes mellitus, 43  % 
were National Cholesterol Education Program–high 
risk, and 11  % had cerebrovascular or peripheral artery 
disease.
Efficacy
Patients were able to successfully self-administer a 
full dose of evolocumab in approximately 95  % of total 
attempts (Fig.  1a) in both studies. Rates of success-
ful self-administration were similar regardless of the 
patients’ dosing schedule (Fig.  1a) or study device 
(Table 2). Subgroup analysis of the primary endpoint by 
screening age and sex (Fig. 1b) did not indicate any dif-
ference between subgroups in the ability to use either 
device.
LDL-C was reduced from baseline to week 6 
(THOMAS-1) or the mean of weeks 10 and 12 
(THOMAS-2) similarly regardless of the patients’ device 
or dosing schedule (Fig.  2). The estimated least squares 
mean change (95  % CI) in THOMAS-1 was −63.4  % 
(−68.7, −58.2) for the autoinjector group and −59.7  % 
(−64.8, −54.7) for the PFS group. In THOMAS-2, the 
estimated least squares mean change (95  % CI) was 
−64.5  % (−69.2, −59.8) for the autoinjector group and 
−67.9 % (−72.6, −63.2) for the AMD group.
Unbound evolocumab serum (PK) and PCSK9 lev-
els (PD) were similar between devices in the THOMAS 
studies (Additional file 1: Supplementary Table 1).
Table 1 Baseline demographics and disease history of patients
Values are presented as number (percent) of patients unless otherwise noted. Percentages may not add up to 100 owing to rounding
AMD automated minidoser, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, NCEP National Cholesterol Education Program, non-
HDL-C non–high density lipoprotein cholesterol, PFS prefilled syringe, SD standard deviation
a LDL-C was based on calculated values unless calculated LDL-C was <40 mg/dL or triglycerides were >400 mg/dL, in which case the ultracentrifugation LDL-C value 










Mean (SD) age, years 60.6 (9.6) 61.2 (11.1) 59.2 (10.0) 60.1 (10.5)
Age group
 <65 years 46 (62) 42 (56) 57 (70) 49 (60)
 ≥65 years 28 (38) 33 (44) 25 (30) 33 (40)
Female sex 26 (35) 36 (48) 39 (48) 39 (48)
Race
 White 58 (78) 62 (83) 75 (92) 69 (84)
 Black or African American 7 (10) 11 (15) 2 (2) 6 (7)
 Asian 7 (10) 2 (3) 3 (4) 4 (5)
 Other 1 (1) 0 2 (2) 3 (4)
 Missing 1 (1) 0 0 0
Hispanic ethnicity 6 (8) 9 (12) 6 (7) 4 (5)
Baseline ezetimibe use 8 (11) 1 (1) 6 (7) 8 (10)
NCEP high risk 38 (51) 31 (41) 29 (35) 37 (45)
NCEP moderate/moderately high risk 25 (34) 29 (39) 36 (44) 33 (40)
Coronary artery disease 20 (27) 13 (17) 13 (16) 12 (15)
Type 2 diabetes mellitus 18 (24) 17 (23) 18 (22) 17 (21)
Hypertension 54 (73) 49 (65) 49 (60) 56 (68)
Cerebrovascular or peripheral artery disease 6 (8) 8 (11) 6 (7) 14 (17)
Mean (SD) baseline LDL-C, mg/dLa 118.1 (28.7) 116.9 (25.0) 117.3 (23.9) 115.3 (27.0)
Mean (SD) HDL-C, mg/dL 50.6 (13.3) 52.1 (14.7) 49.7 (14.6) 50.9 (14.5)
Mean (SD) triglycerides, mg/dL 143.5 (66.2) 138.1 (60.4) 139.9 (48.4) 147.5 (64.8)
Mean (SD) non-HDL-C, mg/dL 146.8 (33.2) 144.6 (30.2) 145.3 (26.3) 144.8 (30.9)
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Safety
Safety data from the THOMAS studies is displayed in 
Table 3. Overall, the AEs in the THOMAS studies were 
of low frequency and severity and were similar between 
groups (25.6–32.9  % for AEs, 0–1.4  % for serious AEs). 
The most commonly occurring AEs in THOMAS-1 
were headache (4.0 %, n = 6), bronchitis (2.0 %, n = 3), 
and abdominal pain (2.0 %, n = 3). The most commonly 
occurring AEs in THOMAS-2 were pain in extremity, 
fatigue, and sinusitis (all 2.0 %, n = 3).
There were five total AEs in four patients leading to 
study drug discontinuation (two serious; n =  2 in auto-
injector group, n = 1 in PFS group, THOMAS-1; n = 1 
in autoinjector group, THOMAS-2) and no preferred 
term was reported more than once for these events. In 
THOMAS-1, one patient (autoinjector group) experi-
enced cerebrovascular accident (serious AE), one subject 
(PFS group) experienced cholecystitis (serious AE) and 
cholelithiasis, and one subject (PFS group) experienced 
renal impairment. These events were not considered 
related to the study drug or device. In THOMAS-2, one 
patient (autoinjector group) experienced injection-site 
hematoma that was not considered related to the study 
drug but was considered related to the study procedures 
and device.
There were four adverse device effects total, all of 
which occurred in THOMAS-2 and were low sever-










































































First administration Second administration
Fig. 1 Proportion of successful home administrations in a overall population and b prespecified subgroups. Q2W biweekly (140 mg), QM monthly 
(420 mg), T-1 THOMAS-1, T-2 THOMAS-2
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Table 2 Successful home administration of evolocumab in THOMAS-1 and THOMAS-2
AMD automated minidoser, CI confidence interval, PFS prefilled syringe
a Week 2 in THOMAS-1, week 4 in THOMAS-2
b Week 4 in THOMAS-1, week 8 in THOMAS-2
THOMAS-1 THOMAS-2
Autoinjector (n = 74) PFS (n = 75) Autoinjector (n = 82) AMD (n = 82)
First administrationa
 No. successful administrations 71 73 77 78
 % (95 % CI) 95.9 (88.7, 98.6) 97.3 (90.8, 99.3) 93.9 (86.5, 97.4) 95.1 (88.1, 98.1)
Second administrationb
 No. successful administrations 68 72 76 79































Fig. 2 Change in LDL-C from baseline to 6 weeks in THOMAS-1 and to the mean of weeks 10 and 12 in THOMAS-2. LDL-C was based on calculated 
values unless calculated LDL-C was <40 mg/dL or triglycerides were >400 mg/dL, in which case the ultracentrifugation LDL-C value from the same 
blood sample was used instead, if available. AI autoinjector, AMD automated minidoser, LDL-C low-density lipoprotein cholesterol, PFS prefilled 
syringe, Q2W biweekly (140 mg), QM monthly (420 mg), SE standard error, T-1 THOMAS-1, T-2 THOMAS-2
Table 3 Safety in THOMAS-1 and THOMAS-2
Values are presented as number (percent) of patients
AEs adverse events, AMD automated minidoser, PFS prefilled syringe
THOMAS-1 THOMAS-2 All
Autoinjector (n = 74) PFS (n = 75) Autoinjector (n = 82) AMD (n = 82) (n = 313)
Total treatment-emergent AEs 20 (27.0) 22 (29.3) 27 (32.9) 21 (25.6) 90 (28.8)
 Grade 3 or 4 2 (2.7) 3 (4.0) 1 (1.2) 1 (1.2) 7 (2.2)
 AEs leading to study drug discontinuation 1 (1.4) 2 (2.7) 1 (1.2) 0 4 (1.3)
  Serious 1 (1.4) 1 (1.3) 0 0 2 (0.7)
  Nonserious 0 1 (1.3) 1 (1.2) 0 2 (0.7)
 Serious AEs 2 (2.7) 3 (4.0) 1 (1.2) 0 6 (1.9)
 Adverse device effects 0 0 2 (2.4) 1 (1.2) 3 (1.0)
 Injection-site reactions 0 0 0 1 (1.2) 1 (0.3)
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injection-site reaction (AMD group); one patient, pain 
in extremity (autoinjector group); and one patient, injec-
tion-site hematoma (autoinjector group). There were no 
deaths in either study. There was one positively adjudi-
cated cardiovascular event; one patient (THOMAS-1, 
autoinjector group) experienced an adjudicated, nonfatal 
ischemic stroke. No binding anti-evolocumab antibodies 
developed during evolocumab treatment.
Discussion
The results of the THOMAS studies indicate patients can 
successfully administer evolocumab in the home-use set-
ting without healthcare provider–supervision. The study 
devices were all comparable with respect to the primary 
endpoint of successful home-use self-administration as 
well as their safety profiles, with comparable rates of injec-
tion-site reactions and adverse device effects. Reduction in 
LDL-C following home-use administration was compara-
ble across dosing regimens and devices. The devices tested 
were safe and well tolerated. AEs in the THOMAS studies 
were similar to AEs of the overall PROFICIO population 
(Koren et al. 2014; Raal et al. 2015; Robinson et al. 2014; 
Sabatine et  al. 2015; Stroes et  al. 2014; Blom et  al. 2014; 
Stein et  al. 2014). Very few adverse device effects were 
reported; also, these events were similar between groups 
and all grade 1 in severity.
Despite the availability of injectable biologics in the 
home-use setting for multiple other conditions (AbbVie 
Inc 2015; Amgen Inc 2015a, 2015b; Janssen Biotech Inc 
2015; Novo Nordisk A/S 2015), injectable treatments are 
fairly new for treatment of dyslipidemia. In 2015, evo-
locumab and alirocumab were approved for treatment 
of hyperlipidemia and mixed dyslipidemia (Amgen Inc 
2015c; Genzyme Corp 2015; Regeneron Pharmaceuticals 
Inc/sanofi-aventis US LLC 2015). Evolocumab is currently 
approved for both monthly and biweekly dosing (Amgen 
Inc 2015c), and alirocumab is approved for biweekly dos-
ing (Regeneron Pharmaceuticals Inc/sanofi-aventis US 
LLC 2015). The addition of a monthly dosing option is 
intended to accomodate patient convenience. Evolocumab 
biweekly dosing involves an autoinjector (AI) or PFS that 
administers 1 mL. Most of the phase 3 evolocumab stud-
ies (Koren et  al. 2014; Raal et  al. 2015; Robinson et  al. 
2014; Sabatine et  al. 2015; Stroes et  al. 2014) included 
in-clinic and at-home dosing using the autoinjector. The 
THOMAS-2 study was the first phase 3 study to use the 
AMD device, which allows monthly dosing with a single 
injection. The THOMAS studies found that after proper 
device administration training, nearly all enrolled patients 
were able to successfully administer evolocumab in the 
home-use setting.
The THOMAS studies were open label because blinded 
allocation to injection devices is not possible. Possible 
limitations include inaccuracy or bias in self-report-
ing for the primary endpoint, but the profound LDL-C 
reduction seen at follow-up in both studies indicates 
that the proportion of successful self-administrations is 
reliable.
Conclusions
The THOMAS-1 and THOMAS-2 studies demonstrate 
that after appropriate training, patients can safely and 
effectively self-administer evolocumab in the home-use 
setting. LDL-C reductions were robust and consistent 
with expectations from the other PROFICIO studies. 
AEs, including injection-site reactions, were infrequent 
and similar between treatment groups. The biweekly and 
monthly dosing regimens were clinically equivalent.
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